Navigation Links
Vion Pharmaceuticals to Host Conference Call to Discuss 2007 Fourth Quarter and Year-End Financial Results
Date:3/14/2008

NEW HAVEN, Conn., March 14 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VIOND) today announced that it would hold a conference call on Tuesday, March 18, 2008 to discuss its 2007 fourth quarter and year-end financial results. The call will begin at 8:30 a.m. Eastern Time.

To participate in the conference call, please dial (800) 510-0146 in the U.S. (617) 614-3449 for international callers) at least 15 minutes before the start of the call. When prompted for a pass code, please enter 81583398.

An audio webcast of the call will be accessible at http://www.vionpharm.com. Those who wish to listen to the conference call on the Web should visit the Investor Relations section of the Company's website at least 15 minutes prior to the event broadcast, and follow the instructions provided to assure that the necessary audio applications are downloaded and installed. These programs can be obtained at no charge to the user.

A replay of the call will be available two hours after the completion of the call at (888) 286-8010 in the U.S., (617) 801-6888 for international callers), pass code 95705866. The replay will be available through Tuesday, April 1, 2008.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a pivotal Phase II trial as a single agent in elderly patients with de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) as a single agent in small cell lung ca
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014  Pfenex Inc. (NYSE MKT: PFNX), ... of high-value and difficult to manufacture proteins including ... reported financial results for the second quarter ended ... completion of our initial public offering, we have ... product candidates, derived from our proprietary protein expression ...
(Date:8/29/2014)... on electrons, but one of the most promising technologies ... based on light (photons) instead of electrons. First, it ... of single photons and control their direction. Researchers around ... achieve this control, but now scientists at the Niels ... of photons emitted one at a time and in ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 The ... $5.6 billion in 2019. It is expected to ... to 2019, and was valued at $1.8 billion ... by Transparency Market Research. , For more information ... http://www.transparencymarketresearch.com/companion-diagnostics-market.html . , The research report, titled “Companion ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 According to a ... Market” the global orthobiologics market was valued at USD 3,754.6 ... worth USD 5,519.9million in 2019at a CAGR of 5.9% from ... 50 years and above is afflicted by bone and joint ... the year 2020. This has and will continue to increase ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Breakthrough in light sources for new quantum technology 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3
... IRVINE, Calif., Feb. 14 Assured Pharmacy,Inc. (OTC ... the,operation of its pharmacy located at 3822 S.E. ... under previous management, and is being,consolidated into Assureds, ... in Portland. Consolidating the Powell Blvd pharmacy allows ...
... East Coast,s Largest Independent Clinical Lab Services Company ... ... N.J., Feb. 14 MedeFile,International, Inc. (OTC Bulletin Board: ... solutions, today announced,that it has signed a collaborative marketing ...
... DANBURY, Conn., Feb. 14 Biodel Inc. (Nasdaq:,BIOD) today ... 2007. The net loss for the quarter was $11.0 ... two pivotal Phase III clinical trials of,VIAject(TM) positions us ... to the FDA by the end of 2008," stated ...
Cached Biology Technology:Assured Pharmacy Consolidates Portland, Oregon Pharmacy 2Assured Pharmacy Consolidates Portland, Oregon Pharmacy 3Hayes Clinical Labs to Market MedeFile's Proprietary Electronic Medical Record Management Solution to Patients 2Hayes Clinical Labs to Market MedeFile's Proprietary Electronic Medical Record Management Solution to Patients 3Hayes Clinical Labs to Market MedeFile's Proprietary Electronic Medical Record Management Solution to Patients 4Biodel Inc. Reports First Quarter Fiscal Year 2008 Financial Results 2Biodel Inc. Reports First Quarter Fiscal Year 2008 Financial Results 3Biodel Inc. Reports First Quarter Fiscal Year 2008 Financial Results 4Biodel Inc. Reports First Quarter Fiscal Year 2008 Financial Results 5Biodel Inc. Reports First Quarter Fiscal Year 2008 Financial Results 6Biodel Inc. Reports First Quarter Fiscal Year 2008 Financial Results 7
(Date:8/29/2014)... To understand how the repeated climatic shifts over ... patterns of genetic diversity, a team of researchers ... Dr. Ana Carnaval developed a new biodiversity metric ... to which the genetic variation within species is ... assistant professor of biology, and 14 other researchers ...
(Date:8/29/2014)... such as the prolific bloomer Emiliania huxleyi , ... discovered. The finding contradicts the common view that ... on scarce supplies of thiamine in the ocean to ... about the ocean," says CIFAR Senior Fellow Alexandra ... paper with CIFAR fellows John Archibald (Dalhousie ...
(Date:8/28/2014)... mobile app called TX Invasives is now available from ... of Texas at Austin for identifying harmful non-native plant, ... species in the United States cause about $137 billion ... agricultural crops, clog waterways, kill native plants and more. ... app for reporting where invasive species occur, we,re more ...
Breaking Biology News(10 mins):CCNY team defines new biodiversity metric 2Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3Mobile app makes ID of harmful plants, insects in Texas a snap 2
... tightly to a tree trunk, at first sight a colugo ... leaps it launches into a graceful glide, spreading wide the ... distances of up to 150m. So, when Greg Byrnes and ... USA, were looking around for a mammal to carry the ...
... prompt people to reach for the greens and go light on ... people tend to eat more-nutritious meals at home than away from ... their emotional states before and after meals, add to mounting evidence ... sugary foods. "Over the course of evolution in a world ...
... scientist-entrepreneur who led efforts to map the first draft ... diploid genome and to construct the first synthetic bacterium ... of Pittsburgh,s Dickson Prize in Medicine. J. Craig ... prestigious honor during Science 2011: Next Gen, a showcase ...
Cached Biology News:Colugos glide to save time, not energy 2Home is where the healthy meal is 2J. Craig Venter, Ph.D., will receive Pitt's Dickson Prize at Science 2011: Next Gen 2J. Craig Venter, Ph.D., will receive Pitt's Dickson Prize at Science 2011: Next Gen 3
Request Info...
...
...
... are available in two product models - the ... models is that the 6000AT+ includes a membrane ... aerosol for improved detection limits and reduced oxides. ... range of elements by 10-40 times. Note that ...
Biology Products: